Search Results

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, shared new clinical data from its ongoing KT-253 Phase 1 trial.

Kymera Therapeutics, Inc. announced new clinical data for KT-253, a first-in-class MDM2 degrader, from its ongoing Phase 1 dose escalation trial will be presented at the American Society of Clinical Oncology Annual Meeting, taking place from May 31 – June 4, 2024, in Chicago, Illinois.

Kymera Therapeutics, Inc. has recently dosed the first patient in the Phase 1 multicenter, open-label, dose-escalation clinical trial evaluating its investigational MDM2 degrader KT-253.

Kymera Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KT-253 for the treatment of Acute Myeloid Leukemia (AML).

Kymera Therapeutics, Inc. presented preclinical data showing that KT-253, a novel MDM2 degrader, inhibited tumor growth as single agent and in combination with venetoclax in AML xenograft models.

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced its decision to discontinue further clinical development of APTO-253.

According to Nova one advisor, the U.S. Home Healthcare market size was valued at US$ 132.9 billion in 2021 and is expected to hit US$ 253.8 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.50% from 2022 to 2030.

Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Public Health Agency of Canada awarded Chimerix a contract up to $25.3 million agreement to procure TEMBEXA®.

On March 29, 2023, Zylox-Tonbridge Medical Technology Co., Ltd. released its annual financial results for 2022.

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, today announced that it has retained global rights to and has sole responsibility for development and commercialization of TRC253 based on Janssen Pharmaceutica N.V.’s (Janssen’s) decision not to exercise its option to reacquire global rights to TRC253 following a review of the